Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Efficient production of recombinant SARS-CoV-2 spike protein using the baculovirus-silkworm system

Ryosuke Fujita a,*, Masato Hino a, Takeru Ebihara b, Takumi Nagasato b, Akitsu Masuda b, Jae Man Lee c, Tsuguru Fujii c, Hiroyuki Mon d, Kohei Kakino b, Ryo Nagai b, Miyu Tanaka b, Yoshino Tonooka b, Takato Moriyama b, Takahiro Kusakabe d

a Laboratory of Sanitary Entomology, Faculty of Agriculture, Kyushu University, Motooka 744, Nishi-ku, Fukuoka, 819-0395, Japan
b Laboratory of Insect Genome Science, Graduate School of Bioresource and Bioenvironmental Sciences, Kyushu University, Motooka 744, Nishi-ku, Fukuoka, 819-0395, Japan
c Laboratory of Creative Science for Insect Industries, Faculty of Agriculture, Kyushu University, Motooka 744, Nishi-ku, Fukuoka, 819-0395, Japan
d Laboratory of Insect Genome Science, Faculty of Agriculture, Kyushu University, Motooka 744, Nishi-ku, Fukuoka, 819-0395, Japan

Article info
Article history:
Received 23 May 2020
Accepted 4 June 2020
Available online 9 June 2020

Keywords:
Silkworm-BmNPV expression system
SARS-CoV-2
Spike protein

A B S T R A C T
In the case of a new viral disease outbreak, an immediate development of virus detection kits and vaccines is required. For COVID-19, we established a rapid production procedure for SARS-CoV-2 spike protein (S protein) by using the baculovirus-silkworm expression system. The baculovirus vector-derived S proteins were successfully secreted to silkworm serum, whereas those formed insoluble structure in the larval fat body and the pupal cells. The ectodomain of S protein with the native sequence was cleaved by the host furin-protease, resulting in less recombinant protein production. The S protein modified in furin protease-target site was efficiently secreted to silkworm serum and was purified as oligomers, which showed immunoreactivity for anti-SARS-CoV-2 S2 antibody. By using the direct transfection of recombinant bacmid to silkworms, we achieved the efficient production of SARS-CoV-2 S protein as fetal bovine serum (FBS)-free system. The resultant purified S protein would be useful tools for the development of immunodetection kits, antigen for immunization for immunoglobulin production, and vaccines.

© 2020 Published by Elsevier Inc.

1. Introduction
Coronavirus disease 2019 (COVID-19) was outbreaking in December 2019, and it rapidly spread worldwide in early 2020 [1]. The pathogen of COVID-19 is a novel coronavirus designated as severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The genetic sequence of SARS-CoV-2 was immediately released in January 2020 [2], and many researchers started to develop detection kits and anti-COVID-19 vaccines [3–6]. Rapid and efficient production of target protein molecules is required to facilitate the development of these tools. For a laboratory-based expression of SARS-CoV-2 S protein, the expression systems using human cultured cell lines have been used [7–10]. Insect cell line Sf9 has also been used for the expression of SARS-CoV-2 S protein as a baculovirus expression vector system (BEVS) [9,11–13]. BEVS is known as an efficient protein expression system with eukaryotic protein folding and modifications. Indeed, structural studies for the recombinant SARS-CoV-2 S protein have been achieved with BEVS [11,12]. These indicate the potency of the BEVS for mass production of SARS-CoV-2 S antigen. However, BEVS using cultured cell lines sometimes requires fetal bovine serum (FBS) for its high protein production performance. Especially for the production of vaccines, the use of FBS should be avoided because it contains the risk of pathogen contamination, such as viruses or prions.

We have previously developed BEVS using Bombyx mori nucleopolyhedrovirus (BmNPV) and silkworm for the production of a variety of recombinant proteins [14–17]. By using the E. coli-based recombinant bacmid system and silkworm, it is possible to produce recombinant BmNPV without using FBS [18]. Therefore, we develop the BmNPV-silkworm expression system for the production of SARS-CoV-2 S protein without using cultured cell lines and FBS. Our data here presented the successful production of the ectodomain of SARS-CoV-2 S protein, which would facilitate developments of
vaccines, virus detection systems, and immunogen detection systems.

2. Materials and methods

2.1. Recombinant virus construction

The cDNA of the SARS coronavirus-2 Spike (S) gene (Accession MN908947.3, position 1–1222) was chemically synthesized (Integrated DNA Technologies Inc.) then cloned into pFastBac1 vector DNA with Gibson-assembly method. In this process, we added the β-sheet domain of CELO long fiber knob (aa 583–590) [19], target sequence of Tobacco Etch virus (TEV) protease, His-tag, and Strep-tag to the C-terminal end of S gene instead of the transmembrane domain. The cloned gene was introduced into Bombyx mori nucleopolyhedrovirus (BmNPV) bacmid (strain Qd04), then recombinant bacmid was extracted from cultured E. coli DH10Bac using Qiagen Midi kit (Qiagen). One microgram of extracted DNA was mixed with 1.6 µl of Avalanche-Everyday transfection reagent (Integrale), then injected to 4th-instar silkworm larvae (1 µg/larvae). The recombinant BmNPV (P1) was recovered from the larvae serum at four days post-transfection (d.p.t.). For the test of the above procedure, we constructed the BmNPV bacmid carrying GFP under the control of cathepsin promoter.

2.2. Recombinant protein purification

All blood was extracted from recombinant BmNPV-infected silkworm larvae (strain d17 or f38) at four days post-infection (d.p.i.). The blood was separated into serum and blood cells by centrifugation (9000 rpm, 30 min). The serum was diluted in a 5-times volume of T-buffer (10 mM Tris-HCl (pH7.5), 250 mM NaCl), and pass through a 0.45 µm filter. The filtrated sample was loaded into the HiTrap excel column (Cytiva) then washed with T-buffer containing 30 mM imidazole. The recombinant protein was eluted out by 2-step with T-buffer containing 100 mM and 500 mM imidazole. The buffer of resultant eluates was replaced with phosphate-buffered saline (PBS), loaded into the Strep-Tactin Superflow column (IBA lifesiences). The column was washed with PBS, and the recombinant proteins were eluted out with PBS containing 2.5 mM deshitiobiotin. The concentration of purified proteins was determined in the PAGE image with a diluted series of control bovine serum albumin.

2.3. SDS-PAGE and western blotting

The serum samples were recovered as described above. The fat bodies of infected larvae were homogenized in buffer (20 mM Tris-HCl (pH7.5), 500 mM NaCl), then sonicated for 10 min. The homogenized samples were centrifuged (9000 rpm, 30 min, 4 °C), and the supernatants and pellets were recovered as soluble and insoluble fractions, respectively. For the analysis of pupae, the homogenized samples were prepared at four days post-infection (d.p.i). Three pupae were homogenized in lysis buffer (20 mM Tris-HCl (pH7.5), 500 mM NaCl, 0.5% CHAPS), sonicated, and centrifuged with the same protocol for fat bodies. The sample was separated in 8%, 7.5%, or 5–20% SDS-PAGE. The gels were stained by the reverse stain method. Briefly, the gels were incubate with Tris-buffered saline with 0.1% Tween 20 (TBST) containing 4% skim milk. The membrane was rinsed in TBST then incubated with anti-SARS-CoV-2 Spike S2 antibody (Sino Biological Inc.). Anti-rabbit IgG HRP-conjugated antibody was used as a secondary reaction, and the signals were visualized using Super Signal West Pico Chemiluminescent Substrate (Thermo Scientific).

2.4. Native PAGE

The samples were mixed with 1/5 volume of native sample buffer (250 mM Tris-HCl (pH 6.8), 0.1% BPP, 40% glycerol), and loaded on the 5–20% gradient gel without heat-denaturing. The proteins were separated in PAGE with native running buffer (25 mM Tris and 192 mM glycine) at 4 °C. The gel was subjected to reverse staining and western blotting, as described above.

3. Results

For the production of candidate recombinant vaccine molecules for SARS coronavirus 2, it is desirable to use the eukaryote system without using fetal bovine serum (FBS). Therefore, we decided to apply the BmNPV-silkworm expression system without using cultured cells [18]. We first determined the efficiency of progeny production of recombinant BmNPV in our method (Fig. 1). The recombinant bacmid carrying GFP gene was transfected to 4th-inst larval larvae of silkworms. At 4-days post-transfection, the silkworms showed GFP expression in the whole body, especially strong fluorescence in head and tail leg regions (Fig. 1B). The progeny viruses (P1 viruses) were recovered from 4 d.p.t. (approximately 100 µl serum from one larva), then ten µl of the diluted series of the P1 viruses were inoculated into day 2 of 5th-instar larvae (6-days after the first transfection). At 2-days post-infection, all the infected larvae showed GFP fluorescence even with the 1 × 102 dilution of P1 viruses (Fig. 1B). Thus, our method achieved efficient production (more than 1 × 105 shots from one larva) of recombinant BmNPV before the same reared series of silkworms reached to the 5th-instar stage.

We constructed recombinant BmNPV bacmid carrying the extracellular domain of the SARS-CoV-2 spike gene. The spike protein of coronavirus has been known to form the trimeric structure on the surface of the virion. We introduced the β-sheet domain of CELO long fiber knob with an expect to facilitate oligomerization [19]. The expected molecular size of the designed recombinant nCoV-S protein was 141 kDa, including peptide tags (Fig. 1C).

We then transfected the recombinant bacmid into 4th-instar larvae and infected P1 progeny viruses to 5th-instar larvae of silkworms as described above. In the SDS-PAGE and western blotting analysis, we could see the expression of nCoV-S in the silkworm serum as a secreted protein, however, the amount of expressed recombinant protein was not so much in comparison of other background proteins (Fig. 2A, left). In the fat bodies of the infected larvae, the recombinant protein appeared as an insoluble fraction with a smeared pattern (Fig. 2A, center). It was also the same in the analysis of the infected pupae (Fig. 2A right). Thus, the recombinant nCoV-S was secreted to blood but seemed to form aggregates with some degradation in the fat bodies and pupal cells.

It has been known that the S protein of SARS-CoV-2 possesses the furin protease-recognition site [20]. Silkworm Bombyx mori encodes some putative furin protease genes in its genome (Accession: PRJNA205630). We considered that the expressed SARS-CoV-2 S protein was targeted by endogenous furin proteases, which worsened the recombinant protein secretion. Therefore, we constructed another recombinant virus with modification in the furin protease-recognition site according to Wrapp's method [7]. We
could detect the significant signal in the serum fraction with the expected molecular size in the expression analysis for the larval blood (Fig. 2B). However, the recombinant protein still formed an insoluble structure in the fat bodies and the pupal cells.

So far, the recombinant proteins were secreted in serum as soluble proteins. We conducted an affinity chromatography purification for these proteins. In the purification nCoV-S with Ni-sepharose column, some ladder pattern was found around 140 kDa molecular size, especially in elution-1 fraction (100 mM imidazole) (Fig. 3, left). The ladder pattern was moderate in elution-2 (500 mM imidazole), suggesting that the ladder pattern around 140 kDa was the background proteins. Therefore, we carried out subsequent Strep-Tactin column purification for elution-1 and -2 of His-tag purification, respectively. The results showed that the purified protein bands were not visible in the SDS-PAGE image but found in western blotting using anti-SARS-CoV-2 spike S2 antibody (Fig. 3, center and right). In the Strep-tag purification of His-tag column elution-1, we could see two bands (approximately 140 kDa and 70 kDa). The bands of 140 kDa seemed to be intact recombinant nCoV-S protein, whereas the 70 kDa protein was considered a furin-digested S2 domain. We could not find a significant signal in the purified fraction from the His-tag elution-2 sample.

We then tried to purify the nCoV-S NF protein, which was expected not to targeted by furin protease. In the Ni-sepharose purification, we could detect the possible recombinant protein bands around 140 kDa molecular weight, although other background proteins appeared (Fig. 4A, left). In the subsequent Strep-Tactin sepharose column purification, we could see the fine bands in elution fractions with expected molecular size (Fig. 4A; center and
right). The western blotting analysis revealed that the eluates were surely the nCoV-S recombinant proteins. Interestingly, we still found the anti-SARS coronavirus S2 antibody-reactive protein with the size of 70 kDa, although the furin-target site was not in the recombinant protein.

The recombinant nCoV-S protein without furin-target sequence was found to be purified in our method with possessing the reactivity for the SARS-CoV-2 spike S2 antibody in denatured PAGE. The purified nCoV-S NF (elution-A and -B in Fig. 4A) were subjected to native PAGE analysis (Fig. 4B). The proteins appeared as broad bands around 700 kDa, and those were immunoreactive for anti S2 antibody. On the other hand, no significant signals were found around the molecular size marker of 146 kDa, which was considered to be the size of the monomeric form of the recombinant protein. These results suggested that the recombinant ectodomain

of SARS-CoV-2 spike protein without furin-target sites expressed in the BmNPV-silkworm system can be purified as an oligomer. Finally, we determined the amount of purified protein in comparison with the dilution series of BSA standards from the PAGE image. The estimated value of the purified protein from 10 ml serum (corresponding to 30–40 larvae) was about 100 μg.

4. Discussion

For a rapid and efficient production of recombinant proteins using the BmNPV-silkworm system, steps of the production of recombinant viruses and the silkworm rearing schedule are sometimes to be a bottleneck. To overcome this issue, we designed the plan to generate the recombinant BmNPV in 4th-instar larvae and express recombinant proteins in the following 5th-instar larvae
(Fig. 1A). The method enables us to purify the recombinant proteins within ten days from the construction of recombinant bacmid, which is completed in the same rearing series of silkworms. Because the production of the recombinant P1 virus reached to more than $1 \times 10^5$ shots from 1 $\mu$g of the extracted bacmid DNA (containing helper plasmids and pFastBac plasmids), it is easy to expand the production scale with the same schedule. Our method presented here was an FBS-free method, which could keep cost low and avoid pathogen contamination from FBS.

We first tried to express the ectodomain of SARS-CoV-2 S protein with the native sequence; however, the purified protein was less, and the S protein seemed to be cleaved. Recent studies demonstrated that SARS-CoV-2 possesses a furin protease-cleavage site in its spike gene [7-9,11,20]. In the BEVS using Sf9 cells, the expressions of the ectodomain of SARS-CoV-2 S protein seemed to be successful, although the native sequence of S protein was partially affected by furin proteases. On the other hand, most of the recombinant nCoV-S protein in the silkworm seemed to be processed by furin protease (Figs. 2A and 3). Because the cleavage by furins is a proprotein processing, the expressed nCoV-S was digested in the cells, resulting in the loss of N-terminal signal peptide from the C-terminal half of S protein (S2 domain). According to this idea, the truncated form of S2 protein could not be secreted to silkworm serum, so we could not find enough nCoV-S in the extracted silkworm serum. Indeed, S protein without furin cleavage site (nCoV-S-NF) was successfully appeared in the silk-processed chromatography of nCoV-S-NF using the Ni-Sepharose column, the recombinant proteins were separated in elution-1 (containing 100 mM imidazole) and elution-2 (containing 500 mM imidazole) (Fig. 4). The denatured PAGE showed that the purified proteins that came from those two fractions showed almost the same in size, suggesting that the components of those fractions consist of the same molecules. On the other hand, the Native PAGE image showed that the significant signals appeared in almost the same position, but the size of lower bands was different. These implied that the secreted nCoV-S-NF formed some different complexes. It might include heterooligomer with a cleaved S2 domain.

In the fat body of infected larvae and the infected pupal cells, nCoV-S was insoluble and appeared as the smeared bands in the PAGE and Western blot images (Fig. 2A). The estimated size of the smeared patterns ranged around 100 kDa, suggested that the nCoV-S was degraded and formed an insoluble complex with other host proteins in the larval fat body and pupal cells. The furin protease would contribute to this degradation because the size of the insoluble protein was larger in nCoV-S-NF, although they still showed smeared pattern in the Western blot images (Fig. 2B).

We successfully purified the ectodomain of SARS-CoV-2 S protein as a secreted oligomer protein. Because the purified nCoV-S-NF was immunoreactive even in the native page, it will be a useful tool for the development of immunodetection kits, antigen for immunization, and also vaccines.
Declaration of competing interestCOI

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

We thank Dr. Banno (National BioResource Project (NBRP), silkworm) for kindly help for rearing silkworms.

References

[1] Coronavirus diseases (COVID-19) pandemic, WHO (n.d.), accessed, https://www.who.int/emergencies/diseases/novel-coronavirus-2019. (Accessed 22 May 2020).
[2] F. Wu, S. Zhao, B. Yu, Y.M. Chen, W. Wang, Z.G. Song, Y. Hu, Z.W. Tao, J.H. Tian, Y.Y. Pei, M.L. Yuan, Y.L. Zhang, F.H. Dai, Y. Liu, Q.M. Wang, J.J. Zheng, L. Xu, E.C. Holmes, Y.Z. Zhang, A new coronavirus associated with human respiratory disease in China, Nature 579 (2020) 265–269, https://doi.org/10.1038/s41586-020-2008-3.
[3] M. Bhattacharya, A.R. Sharma, P. Patra, P. Ghosh, G. Sharma, B.C. Patra, S.-S. Lee, C. Chakraborty, Development of epitope-based peptide vaccine against novel coronavirus 2019 (SARS-COV-2): immunoinformatics approach, J. Med. Virol. (2020), https://doi.org/10.1002/jmv.25736.
[4] Michael S. Diamond, T.C. Pierson, The challenges of vaccine development against a new virus during a pandemic, Cell Host Microbe 27 (2020) 699–703, https://doi.org/10.1016/j.chom.2020.04.021.
[5] Z. Cui, H. Chang, H. Wang, B. Lim, C.-C. Hsu, Y. Hu, H. Jia, Y. Wang, Y. Zeng, M. Ji, W. Liu, C. Inverarity, W.E. Huang, Development of a rapid test kit for SARS-COV-2: an example of product design, Bio-Design Manuf. (2020) 1–4, https://doi.org/10.1007/s42422-020-00075-7.
[6] R. Zhao, M., Li, H. Song, J. Chen, W. Ren, Y. Peng, G.F. Gao, J. Song, Y. Peng, B. Su, X. Guo, Y. Wang, J. Chen, J. Li, H. Sun, Z. Bai, W. Cao, J. Zhu, Q. Zhang, Y. Sun, S. Sun, X. Mao, J. Su, X. Chen, A. He, W. Gao, R. Jin, Y. Jiang, L. Sun, Early detection of SARS-CoV-2 antibodies in COVID-19 patients as a serological marker of infection, Clin. Infect. Dis. (2020), https://doi.org/10.1093/cid/ciaa523.
[7] D. Wrapp, N. Wang, K.S. Corbett, J.A. Goldsmith, C.L. Hisheb, O. Abiona, B.S. Graham, J.S.McClellan, Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation, Science (80-) 367 (2020) 1260–1263, https://doi.org/10.1126/science.aax0922.
[8] A.C. Walls, Y.-J. Park, M.A. Tortorici, A. Wall, A.T. McGuire, D. Veesler, Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein, Cell 181 (2020) 281–292, https://doi.org/10.1016/j.cell.2020.02.058.
[9] J. Wang, Y. Yan, C. Luo, G. Ye, Q. Geng, A. Auerbach, F. Li, Cell entry mechanisms of SARS-CoV-2, Proc. Natl. Acad. Sci. U.S.A. 2020 (2020) 1–8, https://doi.org/10.1073/pnas.2003138117.
[10] W. Tai, L. He, X. Zhang, J. Pu, D. Voronin, S. Jiang, Y. Zhou, L. Du, Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine, Cell. Mol. Immunol. (2020), https://doi.org/10.1038/s41423-020-0400-4.
[11] J. Shang, G. Ye, K. Shi, Y. Wan, C. Luo, H. Aihara, Q. Geng, A. Auerbach, F. Li, Structural basis of receptor recognition by SARS-CoV-2, Nature 581 (2020), https://doi.org/10.1038/s41586-020-2179-y.
[12] J. Lan, J. Ge, J. Yu, S. Shan, H. Zhou, S. Fan, Q. Zhang, X. Shi, Q. Wang, L. Zhang, X. Wang, Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor, Nature 581 (2020) 215–220, https://doi.org/10.1038/s41586-020-2180-5.
[13] Q. Wang, Y. Zhang, L. Wu, S. Niu, C. Song, Z. Zhang, G. Lu, C. Qiao, Y. Hu, K.-Y. Yuen, Q. Wang, H. Zhou, J. Yan, L. Q, Structural and functional basis of SARS-CoV-2 entry by using human ACE2, Cell 181 (2020) 894–904, https://doi.org/10.1016/j.cell.2020.03.045.
[14] T. Yano, J.M. Lee, J. Xu, Y. Morifuji, A. Masuda, M. Hino, D. Morokuma, R. Fujita, M. Takahashi, T. Kusakabe, H. Mon, Expression of the thermostable Moloney murine leukemia virus reverse transcriptase by silkworm-baculovirus expression system, J. Asia Pac. Entomol. 22 (2019) 453–457, https://doi.org/10.1016/j.aspen.2019.02.008.
[15] Y. Kinoshita, J. Xu, A. Masuda, K. Minamihata, N. Kamiya, H. Mon, R. Fujita, T. Kusakabe, J.M. Lee, Expression and purification of biologically active human granulocyte-macrophage colony stimulating factor (hGM-CSF) using silkworm-baculovirus expression system vector, Protein Expr. Purif. 159 (2019) 69–74, https://doi.org/10.1016/j.pep.2019.03.010.
[16] A. Masuda, J.M. Lee, T. Miyata, T. Sato, S. Hayashi, M. Hino, D. Morokuma, N. Karasaki, H. Mon, T. Kusakabe, Purification and characterization of immunogenic recombinant virus-like particles of porcine circovirus type 2 expressed in silkworm pupae, J. Gen. Virol. 99 (2018) 917–926, https://doi.org/10.1099/jgv.0.001087.
[17] M. Yamashita, J. Xu, D. Morokuma, K. Hirata, M. Hino, H. Mon, M. Takahashi, S.M. Hamdan, K. Sakashita, K. Iyama, Y. Banno, T. Kusakabe, J.M. Lee, Characterization of recombinant thermococcus kodakaraensis (KOD) DNA polymerases produced using silkworm-baculovirus expression vector system, Mol. Biotechnol. 59 (2017) 221–233, https://doi.org/10.1007/s12033-017-0008-9.
[18] R. Maesaki, R. Satoh, M. Taoka, T. Kanaba, T. Asano, C. Fujita, T. Fujiwara, Y. Ito, R. Maesaki, R. Satoh, M. Taoka, T. Kanaba, T. Asano, C. Fujita, T. Fujiwara, Y. Ito, T. Isobe, T. Hakoshima, K. Maenaka, M. Mishima, Efficient and cost effective production of active-form human PKB using silkworm larvaes, Sci. Rep. 4 (2014) 1–8, https://doi.org/10.1038/srep06016.
[19] T. Harakuni, K. Andoh, R. Sakamoto, Y. Tamaki, T. Miyata, H. Urefji, K. Yamazaki, T. Arakawa, Fiber knob domain lacking the shaft sequence but fused to a coiled coil is a candidate subunit vaccine against egg-drop syndrome, Vaccine 34 (2016) 3184–3190, https://doi.org/10.1016/j.vaccine.2016.04.005.
[20] B. Coutard, C. Valle, X. de Lamballerie, B. Canard, N.G. Seidah, E. Decroly, The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade, Antivir. Res. 176 (2020) 104742, https://doi.org/10.1016/j.antiviral.2020.104742.
[21] J.A. Jaimes, N.M. Andre, J.S. Chappie, J.K. Millet, G.R. Whittaker, Phylogenetic analysis and structural modeling of SARS-CoV-2 spike protein reveals an evolutionary distinct and proteolytically sensitive activation loop, J. Mol. Biol. 432 (2020) 3309–3325, https://doi.org/10.1016/j.jmb.2020.04.009.
[22] N. Vankadari, J.A. Wilce, Emerging WuHan (COVID-19) coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26, Emerg. Microb. Infect. 9 (2020) 601–604, https://doi.org/10.1093/ems/mbaa058.